// App-Quantinova.ai

EP501 : GLOFITAMAB STEP-UP DOSING (SUD): UPDATED EFFICACY DATA SHOW HIGH COMPLETE RESPONSE RATES IN HEAVILY PRETREATED RELAPSED/REFRACTORY (R/R) NON-HODGKIN LYMPHOMA (NHL) PATIENTS (PTS)

Researchers

Presenter

  • Carmelo Carlo-Stella

Principal Investigators

  • Martin Hutchings

  • Fritz C. Offner

  • Franck Morschhauser

  • Emmanuel Bachy

  • Michael Crump

  • Anna Sureda

  • Gloria Iacoboni

  • Corinne Haioun

  • David Perez-Callejo

  • Linda Lundberg

  • James Relf

  • Emma Clark

  • David Carlile

  • Emily Piccione

  • Anton Belousov

  • Kathryn Humphrey

  • Michael J. Dickinson

Medical Centers

  • F. Hoffmann-La Roche Ltd., Basel, Switzerland

  • Humanitas University and Humanitas Research Hospital, Milano, Italy

  • Hopital Mondor, AP-HP, Creteil, France

  • Vall d'Hebron University Hospital, Barcelona, Spain

  • Princess Margaret Hospital, Toronto, ON, Canada

  • Roche Products Ltd., Welwyn Garden City, United Kingdom

  • Universitair Ziekenhuis Gent, Ghent, Belgium

  • Peter MacCallum Cancer Center, Royal Melbourne Hospital, and University of Melbourne ,Melbourne,Australia

  • Hospices Civils de Lyon, Universite Claude Bernard, Pierre Benite, France

  • Hematology,Institut Català d’Oncologia Hospitalet, IDIBELL, Universidad de Barcelona,Barcelona,Spain

  • Rigshospitalet, Copenhagen, Denmark

  • Hopital Claude Huriez, Centre Hospitalier Regional Universitaire de Lille, Lillie, France

  • Genentech Inc., San Francisco, United States

Locations

  • Switzerland

  • Italy

  • France

  • Spain

  • Canada

  • United Kingdom

  • Belgium

  • Australia

  • Denmark

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Non-Hodgkin's Lymphoma

Biomarkers

  • N/A

Drug/Treatment

  • Obinutuzumab

  • Obinutuzumab Intravenous

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03075696

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved